International Journal of STD & AIDS > Volume 20, Number 10 > Pp. 690-695

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Heystek, M PubMed PubMed Citation Social Bookmarking                      What's this?

Original research articles

A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease

M Heystek MD ^*, J D C Ross MD FRCP   for the PID Study Group

^* Department of Family Medicine, University of Pretoria, Pretoria, South Africa; Whittall Street Clinic, Birmingham, UK

Correspondence to: Dr J D C Ross, Whittall Street Clinic, Whittall Street, Birmingham B4 6DH, UK Email: Jonathan.Ross{at}hobtpct.nhs.uk

This multicentre, double-blind study was undertaken to demonstrate non-inferiority of once-daily oral moxifloxacin compared with combination therapy in the management of acute, uncomplicated pelvic inflammatory disease (PID). Women aged 18 years with PID were randomized to receive moxifloxacin (400 mg once daily) for 14 days or comparator treatment (doxycycline [100 mg twice daily] plus metronidazole [400 mg three times daily] for 14 days, plus one single 500-mg ciprofloxacin dose). Of the 434 valid per protocol (PP) patients, the overall clinical success rates at 2–14 days post-therapy were 96.6% (moxifloxacin) and 98.0% (comparator); moxifloxacin was non-inferior to the comparator regimen both in the PP (95% confidence interval [CI]: –4.5, 1.6) and intent-to-treat (95% CI: –5.8, 6.9) populations. Clinical success rates at 21–35 days post-therapy were 93.8% (166/177; data missing for 47 patients) for moxifloxacin and 91.3% (147/161; data missing for 37 patients) for the comparator. Bacteriological success rates at 2–14 days post-therapy were 92.5% (moxifloxacin) and 88.2% (comparator). Once-daily dosing and proven efficacy suggest that moxifloxacin may be of value in acute, uncomplicated PID.

Key Words: ciprofloxacin • doxycycline • metronidazole • moxifloxacin • pelvic inflammatory disease

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?